US.GILD · Gilead Sciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.001631552812655,
        "turnoverUsdM": 1496.452938,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.GILD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 132.5072,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 6,
      "take_profit_price": 150.6176,
      "target_multiplier": 1.9,
      "technical_strength": 1.8,
      "take_profit_percent": 6.8
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.00326310562531,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 99,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 35
  },
  "market": {
    "ma20": 125.594,
    "ma50": 124.5358,
    "close": 140.97,
    "prevClose": 137.78,
    "avgVolume20": 7028925,
    "volumeRatio": 1.51,
    "changePercent": 2.32
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred+database-backfill-market-proxy"
  },
  "barCount": 150,
  "momentum": {
    "max": 50,
    "result": 35,
    "details": {
      "ret_5d": 0.13557274045432566,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 35,
      "vcp_bonus": 0,
      "vol_ratio": 1.6079444458329453,
      "ret_points": 16,
      "vol_points": 6,
      "range_ratio": 1.079424286614759,
      "volat_points": 0,
      "day_range_pct": 0.02958090373838421,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 1,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 1
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 99,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 17.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 86,
        "contribution": 17.2
      },
      {
        "raw": 9.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 61.33,
        "contribution": 9.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 22.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 74.33,
        "contribution": 22.3
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 64,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 17.2/20分",
      "市場環境分析總分: 9.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 22.3/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 17.2,
      "市場環境": 9.2,
      "情緒分析": 2,
      "技術信號": 22.3,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.6,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 1496.452938,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.GILD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred+database-backfill-market-proxy",
              "vixClose": 16.35
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 122.32855801433648,
                "ma50": 119.96346877259626,
                "name": "QQQ",
                "close": 124.13713218586749,
                "points": 2
              },
              "spy": {
                "ma20": 113.2768836882191,
                "ma50": 110.87278891017002,
                "name": "SPY",
                "close": 114.45487124539912,
                "points": 2
              },
              "source": "twelvedata+fred+database-backfill-market-proxy"
            }
          },
          "atrPct": 3.001631552812655,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140663155,
                "url": "https://finnhub.io/api/news?id=1a3f580daaed6ada4e23836533ca516a5c177b1f290f965def332097bd42447a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1781787605,
                "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know"
              },
              {
                "id": 140662059,
                "url": "https://finnhub.io/api/news?id=23d420fac681049148693abba4d62b0232813a8e77c8964624ccd2d7372ca40f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period.",
                "category": "company",
                "datetime": 1781780968,
                "headline": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140654899,
                "url": "https://finnhub.io/api/news?id=faac09a7f7de9bb4173c55109249682bbd623df9bd8481309582c5dd8cd306af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]",
                "category": "company",
                "datetime": 1781717681,
                "headline": "Gilead Sciences (GILD) Donates Remdesivir to Uganda"
              },
              {
                "id": 140641317,
                "url": "https://finnhub.io/api/news?id=883f1bad6f221a953febfd8f61b3f5b2e96eae9030830b9aa6e21e8eace34177",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.",
                "category": "company",
                "datetime": 1781560804,
                "headline": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know"
              },
              {
                "id": 140629045,
                "url": "https://finnhub.io/api/news?id=174e903c9e447f390e32a6dac302a1f1104fee44e5334ee0f12695e33d55d98b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks. The trial […]",
                "category": "company",
                "datetime": 1781377986,
                "headline": "Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC"
              },
              {
                "id": 140626819,
                "url": "https://finnhub.io/api/news?id=b2fbbe210a4bc729cc6baf59f913fd310c790b697a68515f3826e2d51ade11fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 7 Best Longevity Stocks to Buy Now. On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global […]",
                "category": "company",
                "datetime": 1781347204,
                "headline": "Gilead (GILD) Supports Faster South Africa Access to Lenacapavir"
              },
              {
                "id": 140613106,
                "url": "https://finnhub.io/api/news?id=354c47f8be469cfb23096e022d3c5e07f5a354fe5535d6037e7e94cdecbe457d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]",
                "category": "company",
                "datetime": 1781207705,
                "headline": "Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?"
              },
              {
                "id": 140602140,
                "url": "https://finnhub.io/api/news?id=592e2ef78285f01785e0d1fc325ca29ec5cca97b3fb618753b21f999825dd8c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]",
                "category": "company",
                "datetime": 1781139608,
                "headline": "Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development"
              }
            ],
            "raw_source": [
              {
                "id": 140671728,
                "url": "https://finnhub.io/api/news?id=957e47d41ef4ce6936a64e0270e8698c9ff943155d016110422005d237e83dea",
                "image": "https://image.cnbcfm.com/api/v1/image/108324424-1781858912003-gettyimages-2282248947-epmt00182_bau6eobu.jpeg?v=1781858918&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "U.S. Trade Representative Jamieson Greer said Germany's proposal to reduce spending on medicines was \"a serious step backwards.\"",
                "category": "company",
                "datetime": 1781844424,
                "headline": "U.S. opens tariff probe targeting Germany’s drug pricing policies"
              },
              {
                "id": 140666786,
                "url": "https://finnhub.io/api/news?id=be55fb9c04767324fcd686fca88a9ebdb59737ca1945c7fa3d4dd472f9b73982",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Track weekly dividend updates for Champions, Contenders & Challengers: dividend changes, upcoming ex-dividend dates, and pay dates.",
                "category": "company",
                "datetime": 1781814043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 21"
              },
              {
                "id": 140663154,
                "url": "https://finnhub.io/api/news?id=ed24b4beafbfc166200f2cdc5d6f4785e883c7ea8e905162c48bc84fd2478d32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1781793250,
                "headline": "VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026"
              },
              {
                "id": 140671588,
                "url": "https://finnhub.io/api/news?id=f0d71c5255cfab94c2373150f78683c37cac00577ee9bdaaaf28870836b9e04c",
                "image": "https://image.cnbcfm.com/api/v1/image/108324033-17818001441781800139-46624428423-1080pnbcnews.jpg?v=1781800143&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "The Investment Committee debate whether it's safe to buy the SpaceX dip. Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to detail his latest portfolio moves.",
                "category": "company",
                "datetime": 1781788360,
                "headline": "How to trade the SpaceX dip"
              },
              {
                "id": 140663155,
                "url": "https://finnhub.io/api/news?id=1a3f580daaed6ada4e23836533ca516a5c177b1f290f965def332097bd42447a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1781787605,
                "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know"
              },
              {
                "id": 140662059,
                "url": "https://finnhub.io/api/news?id=23d420fac681049148693abba4d62b0232813a8e77c8964624ccd2d7372ca40f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period.",
                "category": "company",
                "datetime": 1781780968,
                "headline": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140661855,
                "url": "https://finnhub.io/api/news?id=5e7923cb7cbb8ebf12e23d75ac6ca50da2671a001d9cc1305a302d493fbf026a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265088343/image_2265088343.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "ABIVAX plans NDA submission for obefazimod in Q4 2026, with Crohn’s disease Phase 2b data delayed to mid-2027. Learn why ABVX stock is a strong sell.",
                "category": "company",
                "datetime": 1781765611,
                "headline": "Abivax: Safety Signals Loom Ahead Of The NDA Submission"
              },
              {
                "id": 140662896,
                "url": "https://finnhub.io/api/news?id=7a374b874df1851e611bd50d3793e3d9ee958e48d0f751e425bfc9f2cb98b75d",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": " ",
                "category": "company",
                "datetime": 1781719271,
                "headline": "Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years"
              },
              {
                "id": 140654899,
                "url": "https://finnhub.io/api/news?id=faac09a7f7de9bb4173c55109249682bbd623df9bd8481309582c5dd8cd306af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]",
                "category": "company",
                "datetime": 1781717681,
                "headline": "Gilead Sciences (GILD) Donates Remdesivir to Uganda"
              },
              {
                "id": 140651853,
                "url": "https://finnhub.io/api/news?id=9444ccaeda4b24fcef44dac70bdf37a51e2f62ba5ac4d8131f7a8552b7de1480",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1781692131,
                "headline": "1 Cash-Producing Stock Worth Investigating and 2 We Brush Off"
              },
              {
                "id": 140651281,
                "url": "https://finnhub.io/api/news?id=ca6315fb1976875f2c3a05c2f6e021b21a0606468c3a448f64d984ce6fe5581a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.",
                "category": "company",
                "datetime": 1781682060,
                "headline": "The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK"
              },
              {
                "id": 140647921,
                "url": "https://finnhub.io/api/news?id=f9bf47629703209c3e1af6602e954402634d8842d39c9c3ecbbe94a804281c9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.",
                "category": "company",
                "datetime": 1781633820,
                "headline": "FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention"
              },
              {
                "id": 140646203,
                "url": "https://finnhub.io/api/news?id=1653f4271f3d362d17df53a82c6d7a4c322e3a759243ef6c204567337ab013bd",
                "image": "https://image.cnbcfm.com/api/v1/image/108120242-1742822758194-gettyimages-1756846304-omarques_31102023_ILLUS_TECH-13.jpeg?v=1781626849&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1781612712,
                "headline": "Stocks making the biggest moves midday: SpaceX, Lumentum, Huntsman, e.l.f. Beauty, Intel & more"
              },
              {
                "id": 140645979,
                "url": "https://finnhub.io/api/news?id=25e6ec83f34b23006e9bb7e54a6e158e00138e0b5058378acddcbd27f59a2dc4",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.",
                "category": "company",
                "datetime": 1781600754,
                "headline": "Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"
              },
              {
                "id": 140641317,
                "url": "https://finnhub.io/api/news?id=883f1bad6f221a953febfd8f61b3f5b2e96eae9030830b9aa6e21e8eace34177",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.",
                "category": "company",
                "datetime": 1781560804,
                "headline": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know"
              },
              {
                "id": 140640496,
                "url": "https://finnhub.io/api/news?id=bd51084fdda7adc50acb39d1a690cba7e7c1503dc7c656a032876df10d41d64f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., June 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027.",
                "category": "company",
                "datetime": 1781555640,
                "headline": "U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention"
              },
              {
                "id": 140639726,
                "url": "https://finnhub.io/api/news?id=7c876780acc1b39120f8cd87aa780e1faf44c1f2594ce49095d5f076d90d6e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Top 10 Income Stocks with the Highest Upside Potential. On May 22, Reuters reported that Gilead Sciences, Inc. (NASDAQ:GILD) said its experimental drug for a rare and potentially fatal liver infection had received US approval. The U.S. Food and Drug Administration approved Hepcludex for the treatment of […]",
                "category": "company",
                "datetime": 1781552792,
                "headline": "Regulatory Milestone Boosts Gilead’s Presence in Liver Disease Care"
              },
              {
                "id": 140640351,
                "url": "https://finnhub.io/api/news?id=205080b45613684efdfbeb2ad7c4e69581741a754c6afed816ec0c49ef1287f9",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential",
                "category": "company",
                "datetime": 1781541633,
                "headline": "Gilead Sciences New Supplemental Dug Application Accepted By FDA For Yeztugo 300-Mg Tablet; Regulator Sets Feb. 2, 2027 As Prescription Drug User Fee Act Action Date"
              },
              {
                "id": 140636765,
                "url": "https://finnhub.io/api/news?id=6ee0735b35a411e1fe324eaa5de765590a3fa4510a387c5193437c9fd381252a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis (PBC), supporting alkaline phosphatase (ALP) normalization as a treatment goal. The US Food and Drug Administration granted accelerated approval for Livdelzi in PBC. The FDA also approved Hepcludex for the treatment of hepatitis delta virus infection. Gilead Sciences, known for its focus on antiviral and liver disease treatments, is adding fresh momentum to its liver...",
                "category": "company",
                "datetime": 1781521769,
                "headline": "Gilead’s New Liver Approvals Reframe PBC Goals And Revenue Mix"
              },
              {
                "id": 140629045,
                "url": "https://finnhub.io/api/news?id=174e903c9e447f390e32a6dac302a1f1104fee44e5334ee0f12695e33d55d98b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks. The trial […]",
                "category": "company",
                "datetime": 1781377986,
                "headline": "Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC"
              },
              {
                "id": 140626819,
                "url": "https://finnhub.io/api/news?id=b2fbbe210a4bc729cc6baf59f913fd310c790b697a68515f3826e2d51ade11fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 7 Best Longevity Stocks to Buy Now. On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global […]",
                "category": "company",
                "datetime": 1781347204,
                "headline": "Gilead (GILD) Supports Faster South Africa Access to Lenacapavir"
              },
              {
                "id": 140628197,
                "url": "https://finnhub.io/api/news?id=342f0d9583ccd219155d0d5f1f1ab0415c00289a89e45232b5ba2eb96d36b725",
                "image": "https://image.cnbcfm.com/api/v1/image/108222971-1762518699305-gettyimages-2244853460-AFP_83BD63X.jpeg?v=1770822987&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.",
                "category": "company",
                "datetime": 1781337601,
                "headline": "Drugmakers race to find a place in the next wave of obesity drugs  "
              },
              {
                "id": 140617434,
                "url": "https://finnhub.io/api/news?id=b980446f8b77f95dc653795d1866cef97233cf1333f97cdfcdb0bb5b2e5abc11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., June 12, 2026--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company’s long-standing work to address emerging infectious diseases.",
                "category": "company",
                "datetime": 1781267400,
                "headline": "Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief"
              },
              {
                "id": 140622013,
                "url": "https://finnhub.io/api/news?id=ebc0fdf7adc30d701aec7f4d850cec34e337202c8dcab734855189a53b3e5eb2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases."At Gilead, we recognize the urgency and human toll of global health",
                "category": "company",
                "datetime": 1781253235,
                "headline": "Gilead Sciences Donates Over 2,000 Vials Of Remdesivir Intravenous Antiviral Therapy To The Republic Of Uganda To Support Response Efforts Amid The Current Outbreak Of Ebola Bundibugyo Virus Disease"
              },
              {
                "id": 140613106,
                "url": "https://finnhub.io/api/news?id=354c47f8be469cfb23096e022d3c5e07f5a354fe5535d6037e7e94cdecbe457d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]",
                "category": "company",
                "datetime": 1781207705,
                "headline": "Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?"
              },
              {
                "id": 140606111,
                "url": "https://finnhub.io/api/news?id=4dfc679e880e2e6f51912493f9c298c3d8057f854cb56ea11a76300e490e6745",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "SAN FRANCISCO & FOSTER CITY, Calif., June 11, 2026--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, communiti",
                "category": "company",
                "datetime": 1781181000,
                "headline": "National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership"
              },
              {
                "id": 140602140,
                "url": "https://finnhub.io/api/news?id=592e2ef78285f01785e0d1fc325ca29ec5cca97b3fb618753b21f999825dd8c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]",
                "category": "company",
                "datetime": 1781139608,
                "headline": "Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development"
              },
              {
                "id": 140597476,
                "url": "https://finnhub.io/api/news?id=2fd15254ca089f066e9b8660f37bb1dedf7f002db9b8d9081ddb59aab2d3fd2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.",
                "category": "company",
                "datetime": 1781115120,
                "headline": "Can Gilead Sciences HIV Franchise Drive Long-Term Growth?"
              },
              {
                "id": 140593967,
                "url": "https://finnhub.io/api/news?id=f94b337983f7f690c6eb8f668a0bc793bd69c7a586fb408dd3f0efda13351a28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...",
                "category": "company",
                "datetime": 1781100345,
                "headline": "Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential"
              },
              {
                "id": 140588508,
                "url": "https://finnhub.io/api/news?id=7e62c1a3877a8c3e5d6f4cf6dc5ea41cb804ef645c5f10304ee759eae298989a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (GILD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:20 PM EDTCompany ParticipantsDaniel O'Day - Chairman...",
                "category": "company",
                "datetime": 1781035931,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript"
              },
              {
                "id": 140586893,
                "url": "https://finnhub.io/api/news?id=97a2b5bd51652ae116eece4d81d45d52d8b382408147945f1e5270538cd756e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC. Any purchase of ordinary shares done in relation to thi",
                "category": "company",
                "datetime": 1781035260,
                "headline": "Lakefront Announces Initiation of €50 Million Stock Repurchase Program"
              },
              {
                "id": 140586855,
                "url": "https://finnhub.io/api/news?id=3f3fe45104faa35b7e80c3b182ca8a26aae44a95c09720afe180c77085d1ecb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.",
                "category": "company",
                "datetime": 1781033460,
                "headline": "Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study"
              },
              {
                "id": 140583269,
                "url": "https://finnhub.io/api/news?id=1f0764a137af5712ad921dfa770791c34a56d08a30764edbc0656804d413c456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...",
                "category": "company",
                "datetime": 1781024999,
                "headline": "Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus"
              },
              {
                "id": 140585270,
                "url": "https://finnhub.io/api/news?id=071e4439ba6f7c7a02031814c060678dbc089041f0a1d66d87162879ad1639e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...",
                "category": "company",
                "datetime": 1781014097,
                "headline": "Stocks Climb on an AI-Led Rebound"
              },
              {
                "id": 140584684,
                "url": "https://finnhub.io/api/news?id=af4d9e05a1bdf66e8ae4f47cbb5fe4fec3920882e7dd3db2a03e289e63564db7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/09/Feb-19--2020-Foster-City-----Ca-----Usa-.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends",
                "category": "company",
                "datetime": 1781012681,
                "headline": "Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial"
              },
              {
                "id": 140582299,
                "url": "https://finnhub.io/api/news?id=fb6f13d08b877506eee8ba1556c9c2305e7b73adbdfdf44d203c6b6b2cbdd90b",
                "image": "https://image.cnbcfm.com/api/v1/image/108318920-17810228181781022815-46442812417-1080pnbcnews.jpg?v=1781022817&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "The Investment Committee debate the latest Calls of the Day.",
                "category": "company",
                "datetime": 1781008925,
                "headline": "Calls of the Day: Health Care and Materials"
              },
              {
                "id": 140583270,
                "url": "https://finnhub.io/api/news?id=1cc71d25869eaf2f330705eced6ddfbbcf28d84ff7a76d0d98e4404b1472f1b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.",
                "category": "company",
                "datetime": 1781007660,
                "headline": "Merck, Gilead report mixed outcomes in key lung cancer, HIV studies"
              },
              {
                "id": 140580468,
                "url": "https://finnhub.io/api/news?id=02f904ae9ee35fa23e9e584d4dd44ffcf1a34808edee78d04c3865526d64302a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2279799003/image_2279799003.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche deal—review the catalysts, risks, and outlook now.",
                "category": "company",
                "datetime": 1780999140,
                "headline": "Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions"
              },
              {
                "id": 140578906,
                "url": "https://finnhub.io/api/news?id=282b0acc0f4602a60c5b4c1761f3e1203718f72b1855f230f5c83b17a1e873dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials, and they plan global regulatory filings based on these data. At the same time, Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant...",
                "category": "company",
                "datetime": 1780992484,
                "headline": "Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?"
              },
              {
                "id": 140574273,
                "url": "https://finnhub.io/api/news?id=5afdafc5b812f4ef2474cd8c9ad022dbecc85f0e8aa4ef3ff9b9e9dbb7493da1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., & RAHWAY, N.J., June 08, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in pe",
                "category": "company",
                "datetime": 1780950900,
                "headline": "Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment"
              },
              {
                "id": 140574274,
                "url": "https://finnhub.io/api/news?id=9851c4588494797e9eed0a3fa704ef0999c676af4f55ba3adc97103f342c2794",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "RAHWAY, N.J. & FOSTER CITY, Calif., June 08, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer, who",
                "category": "company",
                "datetime": 1780950600,
                "headline": "Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study"
              },
              {
                "id": 140570909,
                "url": "https://finnhub.io/api/news?id=f52754a016f9d0c370a6b1c086de05af6ae8e12d7ce3f39866e5eb1b997ee740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate",
                "category": "company",
                "datetime": 1780938195,
                "headline": "Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead"
              },
              {
                "id": 140574830,
                "url": "https://finnhub.io/api/news?id=4616b8c3c60e800268f7a4463eb4ac9302db38321a4cdfa8f5ff94c7e97708d0",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead's Lenacapavir, a",
                "category": "company",
                "datetime": 1780936570,
                "headline": "Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials"
              },
              {
                "id": 140574831,
                "url": "https://finnhub.io/api/news?id=a38dc9abddae6f90de2e3f79239d3c2735184c129e0b5ab6a7ee7c80935b1c29",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's",
                "category": "company",
                "datetime": 1780936306,
                "headline": "Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC"
              },
              {
                "id": 140569062,
                "url": "https://finnhub.io/api/news?id=b1f0e2fe7635aefbfb3619ee022a1b472335b4f431240f66d4df1363239455f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) faces a potential threat from in vivo CAR-T, an early-stage technology that c",
                "category": "company",
                "datetime": 1780930803,
                "headline": "Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says"
              },
              {
                "id": 140570204,
                "url": "https://finnhub.io/api/news?id=8af80ffed1ce210172db0d8bf47a02b8e6e9867fdbb4c1de86bf284d4745c9e5",
                "image": "https://image.cnbcfm.com/api/v1/image/108226739-1763385616870-gettyimages-2221165792-INDIA_WEGOVY.jpeg?v=1763385675&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.",
                "category": "company",
                "datetime": 1780897205,
                "headline": "Weight loss drug maker sinks 23% after new safety data spooks investors"
              },
              {
                "id": 140564928,
                "url": "https://finnhub.io/api/news?id=5ee6da1334aeba860caa43e3c646ea06cf653359270c54ba1f239ebcb7237076",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2179981073/image_2179981073.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Baron Discovery Fund declined 10.65% in Q1 2026, trailing its benchmark due to software headwinds. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1780882500,
                "headline": "Baron Discovery Fund Q1 2026: Who Moved The Needle"
              },
              {
                "id": 140562428,
                "url": "https://finnhub.io/api/news?id=88e6b6ba4fe31f5a5490c7fd7471f41a222d20a01f69b3be0b2bf5635dd58228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo […]",
                "category": "company",
                "datetime": 1780863092,
                "headline": "Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?"
              },
              {
                "id": 140557341,
                "url": "https://finnhub.io/api/news?id=2878e09367973154141eec31afa0020661bc7c1bd576d0209120d03ab0555d87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammation and immunology pipelines. The centerpiece of this acquisition is gamgertamig (OM336), a clinical-stage T cell engager being developed as […]",
                "category": "company",
                "datetime": 1780807156,
                "headline": "Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline"
              },
              {
                "id": 140549741,
                "url": "https://finnhub.io/api/news?id=28db6194f71b4be09a7ec5f22e9cac6ef5edf01828c51acf8a90a2dbb95d00c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.",
                "category": "company",
                "datetime": 1780755027,
                "headline": "SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens."
              },
              {
                "id": 140550600,
                "url": "https://finnhub.io/api/news?id=b8e9703979166c094762baf9e8125ba8134170120b1dff6a1f025292dce9d3bd",
                "image": "https://image.cnbcfm.com/api/v1/image/108317781-6ED3-MM-A-BLOCK-060526.jpg?v=1780698824&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "'Mad Money' host Jim Cramer looks at what was behind the market sell off.",
                "category": "company",
                "datetime": 1780687216,
                "headline": "Jim Cramer looks ahead to next week's market game plan"
              },
              {
                "id": 140540543,
                "url": "https://finnhub.io/api/news?id=6ae274ba4dadef84e9223b8a1fee577cc7dc735cf893dc0f5dfb3266a035aa22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w",
                "category": "company",
                "datetime": 1780686208,
                "headline": "Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands"
              },
              {
                "id": 140619911,
                "url": "https://finnhub.io/api/news?id=b76f5012bffac7ddad2e89d1c00dcd5dbb4943e7c2d73963cd9c84bfec412596",
                "image": "https://image.cnbcfm.com/api/v1/image/108198691-1757936194403-gettyimages-2221649488-Astrazeneca_Office_Building_in_Shanghai.jpeg?v=1760116750&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.",
                "category": "company",
                "datetime": 1780683976,
                "headline": "AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success"
              },
              {
                "id": 140543177,
                "url": "https://finnhub.io/api/news?id=dac56ba14da07903909a43ce802535e2e0859607b50ad353cf39d06d13b45db3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Get this week’s dividend updates for Champions, Contenders & Challengers—see hikes/cuts, upcoming ex-dividend dates and pay dates.",
                "category": "company",
                "datetime": 1780683596,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 7"
              },
              {
                "id": 140537613,
                "url": "https://finnhub.io/api/news?id=cf97ce1932c366c43d4cc1bd61445c6835b3681308f91e3d1b615d7b8ad9dc1a",
                "image": "https://image.cnbcfm.com/api/v1/image/108317385-17806680741780668071-46364195150-1080pnbcnews.jpg?v=1780668073&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on shares of Five Below.",
                "category": "company",
                "datetime": 1780653836,
                "headline": "Cramer’s Stop Trading: Five Below"
              },
              {
                "id": 140537614,
                "url": "https://finnhub.io/api/news?id=d88cbcce622217c296f32e9fb960103ee76ac4e7793ac966a3cd0f7fc78e9c7e",
                "image": "https://image.cnbcfm.com/api/v1/image/108317374-17806670691780667067-46363966008-1080pnbcnews.jpg?v=1780667069&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Watch the opening bell for the New York Stock Exchange, the Nasdaq and Cboe from June 5, 2026.",
                "category": "company",
                "datetime": 1780652920,
                "headline": "Opening Bell: June 5, 2026"
              },
              {
                "id": 140537324,
                "url": "https://finnhub.io/api/news?id=a48d78e6da9c4481192cb026951d1299d3fc073cc3d783892e3a35cb58a38ef3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/05/Sanofi-SA.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.",
                "category": "company",
                "datetime": 1780642913,
                "headline": "Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative"
              },
              {
                "id": 140533754,
                "url": "https://finnhub.io/api/news?id=1c275c1cc1980bddf98f6298301fe07c26c77b4356821b3147e0bc651ba5aa94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., June 05, 2026--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV.",
                "category": "company",
                "datetime": 1780642800,
                "headline": "Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa"
              },
              {
                "id": 140543807,
                "url": "https://finnhub.io/api/news?id=ddc732f5c426c40a900f7029984eac14787d4d7e4c0cf317b4da9f46ef88b158",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access",
                "category": "company",
                "datetime": 1780631697,
                "headline": "Gilead Backs South Africa, Global Fund Push for HIV Prevention Drug Access"
              },
              {
                "id": 140531823,
                "url": "https://finnhub.io/api/news?id=921c94c4d3c4ce3ef8faa5e6e94cc3bff2fdae3b842e1d4f9120831173fabeed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.",
                "category": "company",
                "datetime": 1780618091,
                "headline": "Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026"
              },
              {
                "id": 140529267,
                "url": "https://finnhub.io/api/news?id=39f356dc7ab1920cd04308aae28c7d4ebb5735ba9a2f39ec21d573bb3ced1e55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif. & MECHELEN, Belgium, June 04, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.",
                "category": "company",
                "datetime": 1780604100,
                "headline": "Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline"
              },
              {
                "id": 140521780,
                "url": "https://finnhub.io/api/news?id=da1f4f67d95a94980840cafa85ece685b2da31644bd17593447ac863c82ab7e6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223482883/image_2223482883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Technology leadership in 2026 is expanding beyond a single AI trade, with innovation accelerating across biotechnology, gaming, space infrastructure, robotics and semiconductors.",
                "category": "company",
                "datetime": 1780561320,
                "headline": "Top Tech Companies To Watch In 2026"
              },
              {
                "id": 140524663,
                "url": "https://finnhub.io/api/news?id=fac3790d77587a546154de4b8923734b4b9386e470a3c9d1563dc0c2c5de9ec0",
                "image": "https://image.cnbcfm.com/api/v1/image/108316285-4ED3-REQ-ASTRAZENECA-CEO-060326.jpg?v=1780515551&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the future is about innovating into new indications with the drugs and technologies they already have in house. He says in the last 3 years the company has averaged one positive trial result readout every month. As far as dabbling in AI, the company created a specialized AI unit to help accelerate research and discovery.",
                "category": "company",
                "datetime": 1780502151,
                "headline": "AstraZeneca CEO: AI is affecting every part of our company"
              },
              {
                "id": 140515090,
                "url": "https://finnhub.io/api/news?id=414aebb02dc12137340ce62c606bffd1c225c8e6a556bda74b0d1240ed603301",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.",
                "category": "company",
                "datetime": 1780499880,
                "headline": "GILD Reports Positive Results From Late-Stage Liver Disease Study"
              },
              {
                "id": 140512272,
                "url": "https://finnhub.io/api/news?id=81084cf4045a8079c00e4a04f48f05271ac29d6006c3cdd85225e1c323f9cc9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Recent share performance and business scale Gilead Sciences (GILD) has seen its stock decline 2.7% over the past day and 4.6% over the past week, adding to a fall of about 3.1% over the past month and 13.9% over the past 3 months. Despite this recent pressure, the company operates at substantial scale. It reports about US$29.7b in annual revenue, net income of roughly US$9.2b, and a market value near US$162.8b, supported by a broad portfolio in HIV, viral hepatitis, oncology and COVID-19...",
                "category": "company",
                "datetime": 1780492329,
                "headline": "Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness"
              },
              {
                "id": 140513303,
                "url": "https://finnhub.io/api/news?id=3c8308d92b3f57ab820b610fada4e7f8aa77fe476133596ee0ab752dba2568e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1780491604,
                "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140511491,
                "url": "https://finnhub.io/api/news?id=c04d81cc538710b6d49ae0c98f9c116dd7fcc085a322db8c6097d92fbf1fcf82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead has touted the potential of its liver disease drug in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.",
                "category": "company",
                "datetime": 1780484972,
                "headline": "Gilead eyes PBC expansion for Livdelzi on positive one-year data"
              },
              {
                "id": 140514376,
                "url": "https://finnhub.io/api/news?id=84ab5ff4db0b4bd1a9fb0ad5a48952e7541e59f09e08268d07aeb4e1dc8cc7fd",
                "image": "https://image.cnbcfm.com/api/v1/image/108315785-4ED1-MC-Emily-060326.jpg?v=1780483719&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Barclays head of U.S. biopharma research Emily Field discusses the biggest themes she came away with from the annual ASCO conference, including RevMed's potentially game-changing treatment for pancreatic cancer.",
                "category": "company",
                "datetime": 1780469785,
                "headline": "Barclays on the top takeaways from the annual ASCO conference"
              },
              {
                "id": 140508765,
                "url": "https://finnhub.io/api/news?id=145beafd3993dd38ed701fcb1217c9011477672c6e5380831f0387494fa66b29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In late May 2026, Gilead Sciences reported new Phase 3 post hoc data showing that Livdelzi produced high, durable reductions in key liver markers for people with primary biliary cholangitis, while also securing accelerated U.S. approval for Hepcludex in chronic hepatitis delta and a positive EU opinion to broaden Trodelvy’s use in metastatic triple-negative breast cancer. These advances highlight how Gilead is consolidating its position in liver disease and oncology by deepening evidence for...",
                "category": "company",
                "datetime": 1780445768,
                "headline": "How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint"
              },
              {
                "id": 140500574,
                "url": "https://finnhub.io/api/news?id=930e33503f9428f065936a1fe6ac690b262605d85ed1a7cfa52855816a03491c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc analysis that showed that Livdelzi® was associated with high and sustained rates of normalization of a key liver marker in people living with primary biliary […]",
                "category": "company",
                "datetime": 1780409641,
                "headline": "Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis"
              },
              {
                "id": 140500575,
                "url": "https://finnhub.io/api/news?id=2e2af51d1b30ac7922c27c4cdcb8087c847325c67797c8cd7d51cb596b7d7d8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that GILD presented long-term interim findings from the ongoing Phase 3 ASSURE study of Livdelzi at the 2026 European Association for the Study […]",
                "category": "company",
                "datetime": 1780409481,
                "headline": "Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety"
              },
              {
                "id": 140516517,
                "url": "https://finnhub.io/api/news?id=ce845a2bcfebeb9af87058836315ad6eb8f7cd5a2178bcd53d3967b5bacc2089",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/02/Feb-19--2020-Foster-City-----Ca-----Usa-.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.",
                "category": "company",
                "datetime": 1780408058,
                "headline": "Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome"
              },
              {
                "id": 140499299,
                "url": "https://finnhub.io/api/news?id=7824b130500b1c5f271e52c4a230b823317349979ca93cf073c60c2a59caa141",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., June 02, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15%",
                "category": "company",
                "datetime": 1780403400,
                "headline": "Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)"
              },
              {
                "id": 140499300,
                "url": "https://finnhub.io/api/news?id=f3d18aeb41e1fbe28c7572b41f1643bdab37d09fe37efe7e848d45d8414434b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "CONSHOHOCKEN, Pa., June 02, 2026--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).",
                "category": "company",
                "datetime": 1780401600,
                "headline": "Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies"
              },
              {
                "id": 140499268,
                "url": "https://finnhub.io/api/news?id=821accb1335fb384e23ea6ac6dc76e201e00d1e0e7a6f542fedca0a6be7e9561",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "As communities across Canada recognize National Indigenous History Month and prepare to mark National Indigenous Peoples Day on June 21, Indigenous leaders and HIV advocates are launching Starting Home Fires, a new Indigenous-led HIV awareness campaign designed to reduce stigma, increase knowledge, and support community-driven conversations about HIV.",
                "category": "company",
                "datetime": 1780401600,
                "headline": "\"Starting Home Fires\" HIV awareness campaign launches during National Indigenous History Month to promote HIV awareness"
              },
              {
                "id": 140500557,
                "url": "https://finnhub.io/api/news?id=1183493ccbd38090056ee103fdee5ffe85498bf9f169172a79dc971c54869ac1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook",
                "category": "company",
                "datetime": 1780394015,
                "headline": "How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks"
              },
              {
                "id": 140497792,
                "url": "https://finnhub.io/api/news?id=710f3aced87019a5d868ae111f67d6ac144a5f6e581d79beeb9081559c7f861a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]",
                "category": "company",
                "datetime": 1780393084,
                "headline": "H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth"
              },
              {
                "id": 140501424,
                "url": "https://finnhub.io/api/news?id=991d4f4d7698ba5d16788fba433b32efdec9cd9105aaa62efcd4bbea23c9f717",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company (NASDAQ:GILD), to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell",
                "category": "company",
                "datetime": 1780390827,
                "headline": "Cencora To Support U.S. Distribution Of Gilead Subsidiary Kite's CAR T-Cell Therapies"
              },
              {
                "id": 140501425,
                "url": "https://finnhub.io/api/news?id=4ce63dba0ec17cbf050f83a206178298375ad3b25f13a62866bb2e944bc769d6",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly",
                "category": "company",
                "datetime": 1780389708,
                "headline": "Gilead Sciences Announces Results Of Phase 3 Study In People With Primary Biliary Cholangitis That Indicated Treatment With Livdelzi Led To Significantly More Patients Achieving Normalization Of Alkaline Phosphatase"
              },
              {
                "id": 140489791,
                "url": "https://finnhub.io/api/news?id=6e63d80bbf11b98da0cf724904f0f1983d1c9c4c9571a0f4b6cb0079be501899",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has shown robust performance, rising 1.6% over the last week and surging 28% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks trading at significant discounts can offer potential opportunities for investors looking to capitalize on undervaluation relative to market growth expectations.",
                "category": "company",
                "datetime": 1780335514,
                "headline": "3 Stocks Estimated To Be Trading At Discounts Ranging From 24% To 49.9%"
              },
              {
                "id": 140486698,
                "url": "https://finnhub.io/api/news?id=4bc4862b8192e1eae95036a402fb86c49ef64b892c2ccf3a57258b5f5751a3c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Safest Dividend Stocks to Buy Right Now. On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company, together with its subsidiary Kite, will present over 25 abstracts at the 2026 ASCO Annual Meeting (May 29 – June 2) and the EHA Congress (June 11 […]",
                "category": "company",
                "datetime": 1780321419,
                "headline": "Gilead (GILD) to Showcase New Cancer Therapy Data"
              },
              {
                "id": 140485845,
                "url": "https://finnhub.io/api/news?id=766594520875362e29ea916d8e3c0408ff9a9e87edbe62be27428f6dda57c772",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.",
                "category": "company",
                "datetime": 1780313922,
                "headline": "Natera And 2 Other Companies That May Be Trading Below Their Estimated Value"
              },
              {
                "id": 140492930,
                "url": "https://finnhub.io/api/news?id=70e091ef81896b0464ba2e009beca1b176ab843e37319ba7bab17a72a60fa913",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": " ",
                "category": "company",
                "datetime": 1780311624,
                "headline": "Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 140476867,
                "url": "https://finnhub.io/api/news?id=d4c34273c00508c62eb672dd324e23d1847e268feeb9570ecf3653eeafd7bf29",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2277689836/image_2277689836.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead (GILD) is rated Hold as BIKTARVY HIV growth offsets VEKLURY drag. Read the full analysis here.",
                "category": "company",
                "datetime": 1780220772,
                "headline": "Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program"
              },
              {
                "id": 140476903,
                "url": "https://finnhub.io/api/news?id=e6b73b44f281cc89130a734a85885956c18abb15d459dad28212654a6cdb24f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1780212328,
                "headline": "Amgen Stock: Is AMGN Outperforming the Healthcare Sector?"
              },
              {
                "id": 140460588,
                "url": "https://finnhub.io/api/news?id=8cfb4616c73fafa4c0ea3b1bca0c412cb34e0a7820d43aa0c8727a12c1a7708b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 28% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future growth.",
                "category": "company",
                "datetime": 1780076294,
                "headline": "Three Stocks That May Be Trading Below Estimated Value In May 2026"
              },
              {
                "id": 140456362,
                "url": "https://finnhub.io/api/news?id=93a98b749862c319a505cd9420cece000d09f1d4da7328993ad69b484ad902bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their estimated value can offer potential opportunities for investors looking to capitalize on market growth while minimizing risk.",
                "category": "company",
                "datetime": 1780054677,
                "headline": "Discover May 2026's Stocks That Could Be Trading Below Estimated Value"
              },
              {
                "id": 140457876,
                "url": "https://finnhub.io/api/news?id=14aa558921e132865e6988b4abb7b461fa5fd5690ab41cb338e8739fccb63df2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2180039238/image_2180039238.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Atea Pharmaceuticals, Inc. gets a Buy ahead of mid-2026 phase 3 HCV data. Click here to read in detail about the AVIR stock.",
                "category": "company",
                "datetime": 1780053592,
                "headline": "Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst"
              },
              {
                "id": 140457721,
                "url": "https://finnhub.io/api/news?id=dd7621a07a2d4bd6571d5159864dcdda33deca18c0e9aa800964fd376ae3a2a4",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (GILD) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 11:00 AM EDTCompany ParticipantsDaniel O'Day - Chairman &...",
                "category": "company",
                "datetime": 1780052052,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript"
              },
              {
                "id": 140458257,
                "url": "https://finnhub.io/api/news?id=b003569df8362c19b4ddc57403712df95e71b0e99f7864a8f1fd3ee8508af0ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.",
                "category": "company",
                "datetime": 1780049820,
                "headline": "Allogene CEO to step down; Agios drug fails key test"
              },
              {
                "id": 140455121,
                "url": "https://finnhub.io/api/news?id=dc871e67dee31ddee8917a262a23df20051b79f188d516d1bd9111cac6f166f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]",
                "category": "company",
                "datetime": 1780034694,
                "headline": "Gilead (GILD) Wins FDA Approval for First HDV Treatment Hepcludex"
              },
              {
                "id": 140450619,
                "url": "https://finnhub.io/api/news?id=0332199b6161885e110f4546c8defd04f2f17d115772e9f1a2f3dffa103469af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report.  The Nasdaq gained 0.9%.  The Dow rose 25 points to post a slight gain and eke out a fresh record, too.",
                "category": "company",
                "datetime": 1779998498,
                "headline": "S&P 500, Nasdaq Rise to Another Record. Software Strikes Back."
              },
              {
                "id": 140442776,
                "url": "https://finnhub.io/api/news?id=0f15e5ee5a8be6ee350f9501795170e2e74c8f735cc68b5164d0d24ca2304452",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Viver Health is proud to announce a culturally adapted U.S. Spanish version of Your Guide to Managing Symptoms from Metastatic Breast Cancer Treatment (Spanish MBC Guide) available to U.S. healthcare professionals (HCPs) and debuting at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO).",
                "category": "company",
                "datetime": 1779966300,
                "headline": "Novel Spanish, Culturally Adapted Metastatic Breast Cancer Symptom Management Guide Debuts at ASCO 2026"
              },
              {
                "id": 140442777,
                "url": "https://finnhub.io/api/news?id=b6c05db129dd9d10b6630961f33350f3dbe9421c3154e1ae072fbc9de011ddaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV patients and the HDV market.",
                "category": "company",
                "datetime": 1779965224,
                "headline": "FDA accelerated approval of Hepcludex significant milestone for US HDV market"
              },
              {
                "id": 140443132,
                "url": "https://finnhub.io/api/news?id=d9aaa021ff58b1e856938b5e504fdd315472d2c919906cb48138449716c6d53f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218694968/image_2218694968.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Screen large-cap dividend stocks using dividend yield + free cash flow yield for stronger income.",
                "category": "company",
                "datetime": 1779958800,
                "headline": "Building A $100,000 All-Weather Dividend Portfolio For May 2026"
              },
              {
                "id": 140434095,
                "url": "https://finnhub.io/api/news?id=fb9c28e77d0660aaded33365df0cd0520c2fdcd0f5964e09aeb5e529444b4a69",
                "image": "https://image.cnbcfm.com/api/v1/image/108312433-17798845071779884504-46193203338-1080pnbcnews.jpg?v=1779884506&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Squawk Box' to discuss the state of the pharma sector, latest GLP-1 developments, weight-loss drug market competition, and more.",
                "category": "company",
                "datetime": 1779870636,
                "headline": "BMO's Evan Seigerman on GLP-1 developments, state of weight-loss drug battle"
              },
              {
                "id": 140436897,
                "url": "https://finnhub.io/api/news?id=910c30a4bca3bbfaf16a616d4fa9773461ac00fd4f56702f896ccbde439780d2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression –– Further Analyses of the Phase 3 ASSURE Study Demonstrate",
                "category": "company",
                "datetime": 1779847533,
                "headline": "Gilead's Livdelzi Shows High And Sustained ALP Normalization In 74% Of Primary Biliary Cholangitis Patients At 24 Months In Phase 3 ASSURE Study"
              },
              {
                "id": 140428960,
                "url": "https://finnhub.io/api/news?id=ff16c6fa1c12ce27bb41bdcfe4a2660e2f2d3947f09ba109ccf8944ceed7160b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "April net investment activity reached a multi-year low. Read what prompted a cautious approach and check out the dividend portfolio here.",
                "category": "company",
                "datetime": 1779837903,
                "headline": "My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys"
              },
              {
                "id": 140422703,
                "url": "https://finnhub.io/api/news?id=e3952ca336087ac592819595b98c309585d4b323a10e214e380ab6e2918c6a5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.",
                "category": "company",
                "datetime": 1779817120,
                "headline": "3 Stocks Estimated To Be Trading Up To 44.8% Below Intrinsic Value"
              },
              {
                "id": 140422063,
                "url": "https://finnhub.io/api/news?id=97f79260ed7d3e8c68c431cbf7f970598d2eef6fddc53c3065581632ce82c98c",
                "image": "https://image.cnbcfm.com/api/v1/image/108312041-17798133331779813331-46177641065-1080pnbcnews.jpg?v=1779813333&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "The Investment Committee debate the latest Calls of the Day.",
                "category": "company",
                "datetime": 1779800524,
                "headline": "Calls of the Day: Eli Lilly, UnitedHealth and the XBI"
              },
              {
                "id": 140419500,
                "url": "https://finnhub.io/api/news?id=57b2f1ae472a37d34da42334841578bc49b9df02b48ccbd5024da94bed8aff50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.",
                "category": "company",
                "datetime": 1779795496,
                "headline": "3 Stocks Estimated To Be Trading At Discounts Of Up To 44.1%"
              },
              {
                "id": 140422115,
                "url": "https://finnhub.io/api/news?id=504cf150f168f74c5e159fbfcd8b80b215d2e98014d4c215534ca6f3bbbc9a55",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": " ",
                "category": "company",
                "datetime": 1779792369,
                "headline": "If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140421426,
                "url": "https://finnhub.io/api/news?id=abfa04ca44e3b2842eef698b7734d3c37c806ea7bbc2bdc6cf41903d26039457",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.",
                "category": "company",
                "datetime": 1779790617,
                "headline": "Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine"
              },
              {
                "id": 140422228,
                "url": "https://finnhub.io/api/news?id=8097279028a3063a7d9c4e9154a6b9fe47593c0f21ffff8615d44e3489f1974a",
                "image": "https://image.cnbcfm.com/api/v1/image/108311840-17797976861779797682-46174227339-1080pnbcnews.jpg?v=1779797685&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the latest developments on the Ebola outbreak, risks to the United States, GLP-1's impact on cancer risks, and more.",
                "category": "company",
                "datetime": 1779783813,
                "headline": "Dr. Scott Gottlieb on Ebola outbreak: This is an outbreak that's out of control in West Africa"
              },
              {
                "id": 140413358,
                "url": "https://finnhub.io/api/news?id=485a28975d394e6189b74c7e2b3a93647d22b23054f152de437af9e91fd8d710",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]",
                "category": "company",
                "datetime": 1779738882,
                "headline": "Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio"
              },
              {
                "id": 140411989,
                "url": "https://finnhub.io/api/news?id=aae60341698c9afbb467a368caf01b45af9716f88ca5f5a0b74660c88674b86e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.",
                "category": "company",
                "datetime": 1779730683,
                "headline": "Three Stocks That May Be Trading Below Their Estimated Value In May 2026"
              },
              {
                "id": 140412004,
                "url": "https://finnhub.io/api/news?id=e2deac2c5d160f3c6f2f709f09b590d2dfd6ce17649eabffdef9fe4fe5d6c49e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.",
                "category": "company",
                "datetime": 1779721140,
                "headline": "GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy"
              },
              {
                "id": 140409869,
                "url": "https://finnhub.io/api/news?id=a88478800b869057ba46d6239d9fb670d36323bde88d99240c357fcbbaa2b300",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust growth, identifying stocks that are potentially trading below their estimated fair value can offer investors opportunities to capitalize on undervalued assets with promising prospects.",
                "category": "company",
                "datetime": 1779709097,
                "headline": "May 2026's Top Stocks That Could Be Trading Below Estimated Fair Value"
              },
              {
                "id": 140405828,
                "url": "https://finnhub.io/api/news?id=0a9b64e88a3d1eb1fb824aae6ffc7c9a349456f5ba17a75518fb56049dd3d7b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "With an annual dividend yield of 2.50%, Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. On May […]",
                "category": "company",
                "datetime": 1779643583,
                "headline": "Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’"
              },
              {
                "id": 140404647,
                "url": "https://finnhub.io/api/news?id=b3339f29a568833f307abd6e9cc28e7e8de2273257a7f67bcd045a27dcbc3b3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel",
                "category": "company",
                "datetime": 1779627834,
                "headline": "Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference"
              },
              {
                "id": 140396317,
                "url": "https://finnhub.io/api/news?id=d2bda1e4c6a61f058f03c8777fc8b942cc67f0188332f951b5280c85801e877e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has returned 3.7% over the last 7 days, 1.1% over the last 30 days, 10.5% year to date, 28.5% over 1 year, 92.9% over 3 years and 144.9% over 5 years, which gives useful context for how expectations and perceived risk have shifted over time. Recent coverage has focused on Gilead Sciences as a large...",
                "category": "company",
                "datetime": 1779520732,
                "headline": "Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 111,
            "discarded_article_count": 87
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.3,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.4,
            "vcp_reason": "站上MA50；升放量(近10日5日)；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 7004610,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8334040,
              "avg_vol_20": 6601845,
              "avg_vol_30": 7004610,
              "range_pct_10": 0.13052421791870616,
              "range_pct_20": 0.15003191459175716,
              "range_pct_30": 0.15003191459175716,
              "up_expand_ok": true,
              "lookback_used": 79,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.1897935788002472,
              "dist_to_20d_high": -0.021299724851841773,
              "down_shrink_days": 2,
              "breakout_level_20d": 138.029999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.8699763531903714
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.001631552812655,
              "turnoverUsdM": 1496.452938,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.GILD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 132.5072,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 6,
            "take_profit_price": 150.6176,
            "target_multiplier": 1.9,
            "technical_strength": 1.8,
            "take_profit_percent": 6.8
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.00326310562531,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 4.2314,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 231.17
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.28
    },
    "kdj": {
      "d": 86.44,
      "j": 105.97,
      "k": 92.95,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 78.34
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 169293800,
      "recentSlope": 4913040,
      "previousSlope": -428220
    },
    "rsi": 77.38,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 120.4128,
      "position": "SAR喺價下",
      "distancePct": 14.58,
      "previousTrend": "上升"
    },
    "ma50": 124.5358,
    "macd": {
      "macd": 3.51947187559837,
      "trend": "強烈看漲",
      "signal": 1.549263911433139,
      "histogram": 1.970207964165231
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 126.6509,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 7
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.51,
      "score": 6,
      "avgVolume": 7028925,
      "currentVolume": 10615400
    },
    "derived": {
      "ma20": 125.594,
      "ma50": 124.5358,
      "prevClose": 137.78,
      "avgVolume10": 8655880,
      "avgVolume20": 7028925,
      "changePercent": 2.32,
      "avgVolumeForScore": 7028925
    },
    "ma_cross": {
      "ma20": 125.594,
      "ma50": 124.5358,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 124.7805,
      "prevMa50": 124.1844,
      "spreadPct": 0.85,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 113.5131,
      "upper": 137.6749,
      "position": "上半部"
    },
    "rsi_short": 95.63,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.51
    }
  }
}

{
  "close": 140.97,
  "volume": 10615400,
  "changePercent": 2.32
}